Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.
Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other investments and board roles include Fusion Pharmaceuticals (Nasdaq: FUSN), Carisma Therapeutics, Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator.